A randomised phase III study on the effect of bortezomib combined with adriamycin, dexamethasone (AD) for induction treatment, followed by high dose melphalan and bortezomib alone during maintenance in patients with multiple myeloma

Authors
Category Primary study
Registry of TrialsISRCTN registry
Year 2005
This article has no abstract
Epistemonikos ID: 6dac1f1b6b1631db2fbfdaf8f400b5ab49fd57f9
First added on: Jan 17, 2025